MedTrace Logo

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

NCT00290407 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-05-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.

Conditions

  • Leukemia, Lymphocytic, Chronic
  • Lymphoma, Small Lymphocytic

Interventions

DRUG

Rituximab

375 mg/m2, IV (in the vein), once a week for 4 weeks

DIETARY_SUPPLEMENT

Beta-Glucan

250 mg, orally (tablet), three times a day for 9 weeks

Sponsors & Collaborators

  • James Graham Brown Cancer Center

    collaborator OTHER

  • University of Louisville

    lead OTHER

Principal Investigators

  • Roger H Herzig, MD · James Graham Brown Cancer Center/University of Louisville

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290407 on ClinicalTrials.gov